Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Pasteur begins influenza vaccine shipment
The first doses of influenza vaccine are being shipped to the US Centers for Disease Control and prevention (CDC) for their distribution in support of the Vaccines for
The first doses of influenza vaccine are being shipped to the US Centers for Disease Control and prevention (CDC) for their distribution in support of the Vaccines for
US patent 7,256,272 covers composition of matter claims for a CD63 targeting antibody and clone. Arius says that the CD63 targeting antibody has the potential to recruit the
The product is AP rated and is equivalent to Nipent by Hospira. Bedford Laboratories will supply latex-free pentostatin for injection as a sterile lyophilized powder in a single-dose
“Age-related macular degeneration continues to be one of the leading causes of blindness in adults today,” said Leonard Schleifer, president and CEO of Regeneron. “Results of early phase
Repaglinide is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with type 2 diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled
Propranolol hydrochloride extended-release (ER) capsules are the generic equivalent of Wyeth Pharmaceuticals’s Inderal LA capsules and available in 60mg, 80mg, 120mg and 160mg doasage strengths. Propranolol ER capsules
According to the researchers, controversy now exists as to the safest and most efficacious way of treating osteoarthritis, particularly with respect to use of NSAIDs, both non-selective and
“We have found that cocaine’s effects on the cardiovascular system can be reversed by the use of a drug called dexmedetomidine, which is currently approved by the FDA
The new study examined whether phenoxodiol could protect against cisplatin-induced neurite inhibition in PC12 cells as an indication of the potential to protect against neuropathy. In the study,
The FDA stated in an action letter that the efficacy data, when compared to reference drugs, were not sufficient for approval. The agency also requested further information regarding